Physician profile
Corey E Mercer
NPI 1750733796
$2,208.90
in general payments reported to CMS, 2019-2025
27 companies · $85.36 in 2025
The $85.36 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,265 · 2022: $839 · 2023: $18.78 · 2025: $85.36.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $104.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $104.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $514.55 | 2021-2025 | |
| Glaxosmithkline, LLC. | $366.57 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $146.17 | 2021-2025 | Airsupra |
| Novo Nordisk INC | $133.68 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $110.77 | 2021 | |
| Novartis Pharmaceuticals Corporation | $107.53 | 2021-2023 | |
| Amgen INC. | $91.59 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $85.30 | 2022 | |
| Corcept Therapeutics | $80.96 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $71.51 | 2021-2022 | |
| Emmaus Medical, INC. | $61.75 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $60.84 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $56.98 | 2022 | |
| Janssen Pharmaceuticals, INC | $53.11 | 2021 | |
| Lilly USA, LLC | $47.72 | 2021-2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $35.06 | 2021 | |
| Phathom Pharmaceuticals, INC. | $33.16 | 2025 | Voquezna |
| Kowa Pharmaceuticals America, INC. | $28.77 | 2022 | |
| Amarin Pharma, INC. | $19.64 | 2021 | |
| Inspire Medical Systems, INC. | $18.27 | 2025 | Inspire |
| Teva Pharmaceuticals USA, INC. | $15.41 | 2021 | |
| Upsher-Smith Laboratories LLC | $14.52 | 2021 | |
| Merck Sharp & Dohme LLC | $14.06 | 2022 | |
| Bioventus LLC | $13.40 | 2022 | |
| Pfizer INC. | $11.77 | 2021 | |
| Hologic Sales and Service, LLC | $11.21 | 2021 | |
| Genentech USA, INC. | $4.60 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Corey Mercer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.